Would you prefer nivolumab/ipilimumab combination over single agent pembrolizumab for a metachronous low volume MSI-H, metastatic colon cancer, with KRAS mutation?

Topics: Gastrointestinal Cancers • Medical Oncology

Answer from: Medical Oncologist at Academic Institution

To date, I don't think there are any single negative or positive predictive markers of response to immunotherapy in dMMR/MSI-High.The ones identified retrospectively on subset analyses include KRAS as you mentioned Other studies with BRAF, Or liver metastatic disease Elderly However, my t...

Comments

Medical Oncologist at Onc San Antonio
Thank you Dr. @Kasi.

Related Questions